Trial Profile
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms AIO-KRK-0214 Study
- 03 Feb 2023 Status changed from active, no longer recruiting to completed.
- 17 Jul 2022 This trial has been completed in Austria(End date;2022-06-01), according to European Clinical Trials Database record.
- 09 Jul 2022 This trial has been completed in Germany(End date;2022-06-01), according to European Clinical Trials Database record.